ASCO clinical practice guideline: systemic therapy for stage IV non–small-cell lung cancer


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-based recommendations to update the American Society of Clinical Oncology ( ASCO ) guideline on systemic therapy for stage IV non–small-cell lung cancer ( NSCLC ).

There is no cure for patients with stage IV NSCLC.

For patients with performance status ( PS ) 0 to 1 ( and appropriate patient cases with PS 2 ) and without an EGFR-sensitizing mutation or ALK gene rearrangement, combination cytotoxic chemotherapy is recommended, guided by histology, with early concurrent palliative care.

Recommendations for patients in the first-line setting include Platinum-doublet therapy for those with PS 0 to 1 ( Bevacizumab may be added to Carboplatin plus Paclitaxel if no contraindications ); combination or single-agent chemotherapy or palliative care alone for those with PS 2; Afatinib, Erlotinib, or Gefitinib for those with sensitizing EGFR mutations; Crizotinib for those with ALK or ROS1 gene rearrangement; and following first-line recommendations or using Platinum plus Etoposide for those with large-cell neuroendocrine carcinoma.
Maintenance therapy includes Pemetrexed continuation for patients with stable disease or response to first-line Pemetrexed-containing regimens, alternative chemotherapy, or a chemotherapy break.

In the second-line setting, recommendations include Docetaxel, Erlotinib, Gefitinib, or Pemetrexed for patients with nonsquamous cell carcinoma; Docetaxel, Erlotinib, or Gefitinib for those with squamous cell carcinoma; and chemotherapy or Ceritinib for those with ALK rearrangement who experience progression after Crizotinib.

In the third-line setting, for patients who have not received Erlotinib or Gefitinib, treatment with Erlotinib is recommended. There are insufficient data to recommend routine third-line cytotoxic therapy.

Decisions regarding systemic therapy should not be made based on age alone. ( Xagena )

Source: ASCO, 2015

XagenaMedicine_2015



Indietro

Altri articoli

Epidermal growth factor receptor inhibitors ( EGFRi ), EGFR tyrosine kinase inhibitors ( TKI ) and anti‐EGFR antibodies commonly develop...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung...


EGFR belongs to the ErbB family of transmembrane tyrosine kinase receptors ( ErbB comprises ErbB1/EGFR/HER1, ErbB2/HER2/NEU, ErbB3/HER3, and ErbB4/HER4 )....


Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this...


Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3...


New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin...


Results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab...